Clinical Trial Supplies Market Size, Share & Trends Analysis Report By Clinical Phase (Phase I, Phase II, Phase III), By Product & Services, By End-Use, By Therapeutic Use, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global clinical trial supplies market size was valued at USD 2.07 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2030. Globalization, the rise in the number of clinical trials, and the number of biologics & biosimilar drugs in clinical trials are among the major factors expected to drive the market growth. The adoption of a supply chain management system is increasing due to rising pressure to reduce R&D expenditure and increase operational efficiency, as clinical trial supplies account for a large share of the total R&D expenditure of biopharmaceutical companies. There has been a significant rise in the number of biologics and temperature-sensitive drugs in clinical trials. As per WHO in 2020, 38.0% of pharmaceutical drugs are temperature-sensitive and 35.0% of late-phase pharmaceutical drugs are biologics.

This number is expected to increase in the future, as the demand for biologics is growing owing to lesser adverse effects as compared to traditional ties for storage of temperature-sensitive drugs. Hence, the rise in the number of biologics in clinical trials is expected to increase the demand for cold chain facilities. It has been estimated that eight out of the top ten biopharmaceutical products will require cold chain facilities by 2022. The high demand for biosimilars in developing as well as developed economies is expected to further boost the cold chain supply, thereby contributing to the growth of the clinical trial supplies industry over the forecast period.

Most clinical trials are currently being conducted in developing economies. The increasing cost of clinical trials and complications in the recruitment of patients have encouraged biopharmaceutical companies to outsource clinical trials to regions such as Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East. Disease variation in developing economies further aids biopharmaceutical companies to perform clinical trials on rare diseases. Some regions, such as Asia Pacific, also provide greater economic benefits to biopharmaceutical companies, as governments in Singapore and China allocate funds to promote biomedical research. In Latin America, patient recruitment is easy due to reduced language barriers, which can help obtain informed consent easily, resulting in a faster clinical trial process.

Clinical Phase Insights

In 2022, the phase III clinical trial supplies segment accounted for the largest market share of 52.7%. Phase III clinical trials are more complex than other phases. Although the number of drugs in this phase is comparatively low, the complexity associated with this phase is the highest. The failure rate in this phase is the highest as the sample size and study design require complex dosing at an optimum level. The loss associated with the failure is with respect to human and financial, and most of the failures are due to non-compliance with safety & efficacy standards. Such a scenario may surge the demand for efficient supply chain and logistics, which, in turn, is expected to positively impact market growth.

Based on phases, the clinical trial supplies market has been segmented into Phase I, phase II, phase III, and others. Phase I clinical trials are anticipated to register the fastest CAGR growth of 7.0% during the forecast period. This is attributed to the large influx of phase I trials for COVID-19 treatment and prevention. A small sample population and high capital investment are major factors responsible for outsourcing the majority of clinical trials. The increase in the number of phase I clinical trials being outsourced and the globalization of clinical trials are expected to drive the market for clinical trial supplies for phase I.

Product & Services Insights

In 2022, the supply chain management segment held the largest market share with 46.6%. This scenario exists in most regions worldwide, except in the U.S., wherein the manufacturing segment is also expected to grow at a lucrative rate. The pandemic led to a wide disruption in the supply chain and its impact on the lives of the citizens of the country. This propelled the U.S. to become even more self-reliant eventually focusing more on manufacturing services. The product/service segment for the clinical trial supplies industry includes several processes, from drug development to logistics to distribution. Based on the type of products & services, clinical trial supplies industry is divided into three major categories, which comprise all the aspects of clinical trial supplies. These include manufacturing, storage and distribution, and supply chain management.

The manufacturing segment is anticipated to witness considerable growth at a CAGR of over 6.0% during the forecast period. The rise in the number of clinical trials has resulted in high demand for material supplies, which further increases the demand for quality drugs. Complex molecules and high demand for biologics are expected to boost the manufacturing segment of the global clinical trial supplies industry. The majority of material supplies are outsourced, which drives the demand for efficient clinical trial supplies. Outsourcing in manufacturing can be attributed to the introduction of new technologies to manufacture complex molecules and an increase in the demand for developing cost-efficient products.

Therapeutic Use Insights

In terms of therapeutic area, oncology accounted for the largest market share of 38.8% in 2022 owing to the presence of a huge R&D pipeline of oncology drugs. The majority of oncology drugs require temperature-sensitive distribution, which is expected to fuel the demand for cold chain distribution. Oncology clinical trials are designed to diagnose, manage, and treat cancer & associated symptoms. Clinical trial supplies in oncology include primary and secondary packaging. The primary objective of packaging is to improve patient compliance. Packaging must protect vials from leakage and gases from aerosolizing.

On the other hand, cardiovascular disease is anticipated to register the fastest CAGR of 6.9% during the forecast period. Cardiovascular diseases are known to be the leading cause of death globally. According to the latest study published by CDC, one person dies every 33 seconds in the United States from cardiovascular disease. Globally, the highest mortality rates attributed to CVD in 2020 were in Central Asia and Eastern Europe. Also, it was estimated that 244.1 million people are living with ischemic heart disease (IHD) globally. Thus, such factors are anticipated to propel segment growth during the forecast period. Based on the therapeutic area, the segment is majorly categorized into oncology, central nervous system disorders, cardiovascular diseases, infectious diseases, metabolic disorders, and others.

End-use Insights

Pharmaceuticals accounted for the largest market share of 42.2% in 2022. Pharmaceutical companies spend substantial investments in research and development to create novel medications and treatments. To acquire information about the efficacy and safety of their products, clinical trials are an essential step in the drug development process. Therefore, based on end-use, the clinical trial supplies industry is segmented into four types, which include pharmaceuticals, biologics, medical devices, and others.

There has been a steady decrease in pharmaceutical drugs in the R&D pipeline as it has been substituted by biological drugs, which is expected to have a slightly negative impact on segment growth during the forecast period. Pharmaceutical drugs are slowly being replaced by biologics, especially in the category of topmost innovative drugs. Although pharmaceutical drugs account for the highest number of drugs in the clinical trial segment, the growing number of biological drugs is likely to have an impact on this number. However, the demand for safe, efficacious, and cost-effective medicines is expected to fuel the development of enhanced pharmaceutical drugs, thereby propelling segment growth.

Biologics is anticipated to register the fastest CAGR growth of 6.7% during the forecast period owing to an increase in the demand for safe and efficacious drugs with lesser adverse effects. An increase in the incidence of cancer and chronic diseases is also expected to fuel the growth of biologics in clinical trials. In addition, an increase in the number of biologics in the clinical trial segment is expected to drive the cold storage and distribution market. It is also expected to increase the adoption of newer technologies for better supply chain management.

Regional Insights

North America accounted for the largest market share of 55.4% in 2022. The country conducts the highest number of clinical trials among all regions, which is a major driver for the growth of the clinical trial supplies industry in this region. An increase in the number of clinical trials & players in the clinical trial supplies industry and the availability of advanced technology are among the factors responsible for the dominance of this region. The majority of the clinical trials are conducted in countries such as the U.S. and Canada in the region. For instance, in 2022, according to the WHO International Clinical Trials Registry Platform (ICTRP), there were approximately 11,935 clinical trials performed in the U.S.

Asia Pacific is anticipated to grow at the fastest CAGR of 7.1% during the forecast period. The tremendous growth in clinical research is expected to drive the growth of the clinical trial supplies industry in the region. The primary factors driving the growth of clinical research in these regions are the low cost per patient in Asia Pacific countries and the presence of a diverse group of patients that are easy to recruit.

Key Companies & Market Share Insights

The major players operating across the clinical trial supplies market are focused on the adoption of in-organic strategic initiatives such as mergers, partnerships, acquisitions, etc. For instance, in March 2023, Calyx, an eClinical regulatory services, and solutions provider announced the availability through a simulation of Calyx supply, a clinical trial supply forecasting service available through the company's in-house expert statistical design and trial supplies consultants. Moreover, in April 2021, Catalent expanded capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies. Some prominent players in the global clinical trial supplies market include:

• Almac Group

• Biocair

• Catalent Inc.

• KLIFO

• Movianto

• PCI Pharma Services

• Sharp Services, LLC

• Thermo Fischer Scientific Inc.

• Marken

• PAREXEL International Corporation

Recent Developments

• In July 2023, Almac Sciences announced the opening of a custom-built GMP warehouse and dispatch hub at Almac Group’s global headquarters in Craigavon, UK. The facility will support all the manufacturing and lab activities of Active Pharmaceutical Ingredients from development to their commercialization.

• In June 2023, Marken unveiled the Marken Monarch in partnership with SkyCell. The container solution would allow clients to leverage Marken’s worldwide network and SkyCell’s pallet shipper for shipping essential drug products, utilizing features such as optimal protection and efficient temperature control.

• In May 2023, Catalent announced the expansion of its capabilities and services at its Shiga, Japan facility, through the inclusion of cryogenic offerings for addressing clinical supply demand concerning cell and gene therapy development. It continues the company’s strategy to improve its advanced therapy capabilities for clinical supply, following similar investments at its facilities in Singapore, Philadelphia, and Shanghai.

• In April 2023, Catalent announced the commencement of the construction of an expansion project at the company’s clinical supply facility located in Schorndorf, Germany. The facility will see an increase in the capacity for the handling and storage of clinical trial supply materials at controlled room temperatures, while also creating space for accommodating the company’s FastChain demand-led supply service.

• In September 2022, Parexel announced the opening of a clinical trial supplies and logistics depot in Suzhou, China. This becomes the latest addition to the company’s global network of depots and Coordination Hub and Distribution Centers, after Berlin, Buenos Aires, Pennsylvania, São Paulo, and Singapore.

• In July 2022, Sharp announced the expansion of the company’s clinical services offerings at its Heerenveen facility in the Netherlands. The facility has seen the addition of secondary packaging and labeling services for supporting open, randomized clinical trials to its existing clinical storage and distribution offerings.

• In June 2022, Biocair announced the opening of the company’s new operational hub in Paris, thus expanding its European network. The hub has been rolled out in phases by the company’s France team, with the first phase starting in April 2022, which included the setup of a GDP-compliant warehouse with freezers, fridges, and temperature-controlled packaging.

• In December 2021, PCI Pharma Services announced the completion of the acquisition of Lyophilization Services of New England, Inc. (LSNE), a notable CDMO based in New Hampshire, US. The acquisition has helped PCI in enhancing its expertise in the areas of clinical trial supply, pharmaceutical packaging, and specialty manufacturing.

Global Clinical Supplies Market Report Scope

Global Clinical Trial Supplies Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global clinical trial supplies market report based on clinical phase, product & services, therapeutic use, end-use, and region:

• Clinical Phase Outlook (Revenue, USD Billion, 2018 - 2030)

  • Phase I

  • Phase II

  • Phase III

  • Other

• Product & Services Outlook (Revenue, USD Billion, 2018 - 2030)

  • Manufacturing

  • Storage & Distribution

    • Cold chain distribution

    • Non-cold chain

  • Supply chain management

• End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Pharmaceutical

  • Biologics

  • Medical device

  • Others

• Therapeutic Use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Oncology

  • CNS

  • Cardiovascular

  • Infectious disease

  • Metabolic disorders

  • Others

• Regional Outlook (Revenue, USD Billion, 2018-2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait